Cargando…

Drug use for gastrointestinal symptoms during pregnancy: A French nationwide study 2010–2018

PURPOSE: To describe drug prescription for gastrointestinal symptoms during pregnancy. METHODS: Using the French national health database, we identified pregnancies ending with a birth between April 2010 and December 2018, in France. We studied prescription of antacids, antispasmodics, antinauseants...

Descripción completa

Detalles Bibliográficos
Autores principales: Meyer, Antoine, Fermaut, Marion, Drouin, Jérôme, Carbonnel, Franck, Weill, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822332/
https://www.ncbi.nlm.nih.gov/pubmed/33481904
http://dx.doi.org/10.1371/journal.pone.0245854
Descripción
Sumario:PURPOSE: To describe drug prescription for gastrointestinal symptoms during pregnancy. METHODS: Using the French national health database, we identified pregnancies ending with a birth between April 2010 and December 2018, in France. We studied prescription of antacids, antispasmodics, antinauseants, laxatives and antidiarrheals during pregnancy, between two trimesters before and two trimesters after delivery. We also assessed hospitalization for gastrointestinal symptoms during pregnancy. RESULTS: Among 6,365,471 pregnancies, 4,452,779 (74.0%) received at least one gastrointestinal drug during pregnancy; 2,228,275 (37.0%) received an antacid, 3,096,858 (51.5%) an antispasmodic, 1,861,731 (31.0%) an antinauseant, 919,116 (15.3%) a laxative and 617,808 (10.3%) an antidiarrheal. Prescription of proton pump inhibitors doubled from 12.2% in 2010 to 26.0% in 2018, while domperidone use decreased from 18.3% in 2010 to 2.2% in 2018. In addition, prescription of antacids increased from 7.0% during the trimester before pregnancy to 11.8% during the 1(st) trimester, 17.0% during the 2(nd) trimester and 23.4% during the 3(rd) trimester. Antispasmodic use was 10.6% during the trimester before pregnancy, 23.1% during the 1(st) trimester, 25.2% during the 2(nd) trimester and 24.0% during the 3(rd) trimester. Prescription of antinauseant drugs increased from 5.0% during the trimester before pregnancy to 25.7% during the 1(st) trimester, then decreased to 6.4% during the 2(nd) trimester and 3.2% during the 3(rd) trimester. Nausea/vomiting was the most common cause of hospitalization for gastrointestinal symptoms or diseases during pregnancy, although it accounted for only 1.0% of pregnancies. CONCLUSIONS: Approximately three-quarters of women use drugs for gastrointestinal symptoms during pregnancy in France. Prescription of gastrointestinal drugs during pregnancy should be the subject of more detailed risk-benefit assessment and recommendations.